
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Tscan Therapeutics Inc (TCRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TCRX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $8.57
1 Year Target Price $8.57
4 | Strong Buy |
4 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.76% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.71M USD | Price to earnings Ratio - | 1Y Target Price 8.57 |
Price to earnings Ratio - | 1Y Target Price 8.57 | ||
Volume (30-day avg) 8 | Beta 0.99 | 52 Weeks Range 1.02 - 6.22 | Updated Date 08/15/2025 |
52 Weeks Range 1.02 - 6.22 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.33 | Actual -0.28 |
Profitability
Profit Margin - | Operating Margin (TTM) -1256.6% |
Management Effectiveness
Return on Assets (TTM) -26.77% | Return on Equity (TTM) -63.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -18631133 | Price to Sales(TTM) 14.76 |
Enterprise Value -18631133 | Price to Sales(TTM) 14.76 | ||
Enterprise Value to Revenue 7.64 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 52471400 | Shares Floating 40823939 |
Shares Outstanding 52471400 | Shares Floating 40823939 | ||
Percent Insiders 0.23 | Percent Institutions 81.84 |
Upturn AI SWOT
Tscan Therapeutics Inc
Company Overview
History and Background
Tscan Therapeutics, Inc. is a biopharmaceutical company focused on developing T-cell receptor (TCR)-engineered T cell therapies for the treatment of cancer. Founded in 2018, it has advanced several TCR-T cell therapy candidates into clinical development.
Core Business Areas
- Oncology: Developing and commercializing TCR-T cell therapies to treat various cancers.
Leadership and Structure
The leadership team consists of experienced executives in the biopharmaceutical industry. The company has a traditional biotech organizational structure with departments focusing on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- TSC-100: A TCR-T cell therapy targeting minor histocompatibility antigens (miHAs) for the treatment of hematologic malignancies post allogeneic hematopoietic cell transplantation (allo-HCT). Competitors include companies developing cell therapies for similar indications, such as bone marrow transplant complications.
- TSC-101: A TCR-T cell therapy for solid tumors. Competitors include companies developing cell therapies or other immune-oncology therapies for solid tumors.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immuno-oncology and gene editing technologies. It is a highly competitive and innovative field.
Positioning
Tscan Therapeutics focuses on TCR-T cell therapies, which allows them to target both hematologic malignancies and solid tumors. Their competitive advantage lies in their TCR discovery platform and miHA target selection.
Total Addressable Market (TAM)
The TAM for cell therapies is projected to reach tens of billions of dollars. Tscan Therapeutics is positioned to capture a share of this market by developing TCR-T cell therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Proprietary TCR discovery platform
- Experienced management team
- Clinical-stage pipeline
- Focus on validated targets
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Manufacturing complexities of cell therapies
- Limited commercial infrastructure
Opportunities
- Expanding pipeline with additional TCR-T cell therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals
Threats
- Competition from other cell therapy companies
- Clinical trial failures
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- BMY
- GILD
- NVS
Competitive Landscape
Tscan Therapeutics competes with other cell therapy companies. Its advantage lies in its TCR discovery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data will be added when available.
Future Projections: Future projection data will be added when available.
Recent Initiatives: Recent initiatives include advancing clinical trials for TSC-100 and TSC-101, expanding TCR discovery efforts, and securing partnerships.
Summary
Tscan Therapeutics is a clinical-stage biopharmaceutical company focused on TCR-T cell therapies. Its strengths include its proprietary technology, but it faces risks associated with clinical development and competition. The company needs to successfully navigate the regulatory landscape and demonstrate clinical efficacy to achieve long-term success. They need to watch out for cash burn as they need funding until they are making substantial revenues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tscan Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-07-16 | CEO & Director Dr. Gavin MacBeath Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 194 | Website https://www.tscan.com |
Full time employees 194 | Website https://www.tscan.com |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.